Association between functional SIRT1 polymorphisms and the clinical characteristics of patients with autoimmune thyroid disease

References

• Weetman, A. P. 2000. Chlonic autoimmune thyroiditis. In The Thyroid: A Fundamental and Clinical Text, L. E. Braverman, and R. Utiger, eds. Lippincott Williams & Wilkins, Philadelphia, PA. p. 721–732
   Google Scholar
• Menconi, F., Y. L. Oppenheim, and Y. Tomer. 2008. Graves’ disease. In Diagnostic Criteria in Autoimmune Diseases, Y. S. Cervera, and R. Gershwin, eds. Humana Press, Totowa, NJ. p. 231–235
   Google Scholar
• Amino, N., S. R. Hagen, N. Yamada, and S. Refetoff. 1976. Measurement of circulating thyroid microsomal antibodies by the tanned red cell haemagglutination technique: its usefulness in the diagnosis of autoimmune thyroid diseases. Clin. Endocrinol. (Oxf). 5: 115–125
   PubMed Web of Science ®Google Scholar
• Yoshida, H., N. Amino, K. Yagawa, et al. 1978. Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. J. Clin. Endocrinol. Metab. 46: 859–862
   PubMed Web of Science ®Google Scholar
• Haigis, M. C., and L. P. Guarente. 2006. Mammalian sirtuins – emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20: 2913–2921
   PubMed Web of Science ®Google Scholar
• Kaeberlein, M., M. McVey, and L. Guarente. 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13: 2570–2580
   PubMed Web of Science ®Google Scholar
• Howitz, K. T., K. J. Bitterman, H. Y. Cohen, et al. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191–196
   PubMed Web of Science ®Google Scholar
• Kojima, K., R. Ohhashi, Y. Fujita, et al. 2008. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373: 423–428
   PubMed Web of Science ®Google Scholar
• Ford, J., M. Jiang, and J. Milner. 2005. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65: 10457–10463
   Google Scholar
• Yeung, F., J. E. Hoberg, C. S. Ramsey, et al. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23: 2369–2380
   PubMed Web of Science ®Google Scholar
• Zhu, X., Q. Liu, M. Wang, et al. 2011. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One 6: e27081
   PubMed Web of Science ®Google Scholar
• Sequeira, J., G. Boily, S. Bazinet, et al. 2008. Sirt1-null mice develop an autoimmune-like condition. Exp. Cell Res. 314: 3069–3074
   PubMed Web of Science ®Google Scholar
• Zhang, J., S. M. Lee, S. Shannon, et al. 2009. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 119: 3048–3058
   PubMed Web of Science ®Google Scholar
• Beier, U. H., L. Wang, T. R. Bhatti, et al. 2011. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol. Cell Biol. 31: 1022–1029
   PubMed Web of Science ®Google Scholar
• Biason-Lauber, A., M. Boni-Schnetzler, B. P. Hubbard, et al. 2013. Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab. 17: 448–455
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, F. Hayashi, et al. 2013. The association between a functional polymorphism in the CD24 gene and the development of autoimmune thyroid diseases. Tissue Antigens 81: 161–163
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, Y. Katsumata, et al 2013. Different genotypes of a functional polymorphism of the TSHR gene are associated with the development and severity of Graves’ and Hashimoto’s diseases. Tissue Antigens. 82: 288–290
   PubMedGoogle Scholar
• Inoue, N., M. Watanabe, M. Morita, et al. 2011. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin. Exp. Immunol. 163: 318–323
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, M. Morita, et al. 2010. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin. Exp. Immunol. 162: 402–406
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, T. Nobuhara, et al. 2013. The GG genotype of the -1125G/T polymorphism in the EPO gene protects against the development of Graves’ disease. Immunol. Lett. 156: 156–158
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, M. Wada, et al. 2013. IL-10 -592A/C polymorphism is associated with severity of Hashimoto’s disease. Cytokine 64: 370–374
   PubMed Web of Science ®Google Scholar
• Inoue, N., M. Watanabe, H. Yamada, et al. 2013. Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies. J. Clin. Immunol. 32: 1243–1252
   Web of Science ®Google Scholar
• Morita, M., M. Watanabe, N. Inoue, et al. 2012. Functional polymorphisms in TBX21 and HLX are associated with development and prognosis of Graves’ disease. Autoimmunity 45: 129–136
   PubMed Web of Science ®Google Scholar
• Tomizawa, R., M. Watanabe, N. Inoue, et al. 2011. Association of functional GITR gene polymorphisms related to expression of glucocorticoid-induced tumour necrosis factor-receptor (GITR) molecules with prognosis of autoimmune thyroid disease. Clin. Exp. Immunol. 165: 141–147
   PubMed Web of Science ®Google Scholar
• Yamada, H., M. Watanabe, T. Nanba, et al. 2008. The +869T/C polymorphism in the transforming growth factor-beta1 gene is associated with the severity and intractability of autoimmune thyroid disease. Clin. Exp. Immunol. 151: 379–382
   PubMed Web of Science ®Google Scholar
• Ito, C., M. Watanabe, N. Okuda, et al. 2006. Association between the severity of Hashimoto’s disease and the functional +874A/T polymorphism in the interferon-gamma gene. Endocr. J. 53: 473–478
   PubMed Web of Science ®Google Scholar
• Nanba, T., M. Watanabe, T. Akamizu, and Y. Iwatani. 2008. The -590CC genotype in the IL4 gene as a strong predictive factor for the development of hypothyroidism in Hashimoto disease. Clin. Chem. 54: 621–623
   PubMed Web of Science ®Google Scholar
• Zarrabeitia, M. T., C. Valero, J. C. Martin-Escudero, et al. 2012. Association study of sirtuin 1 polymorphisms with bone mineral density and body mass index. Arch. Med. Res. 43: 363–368
   PubMed Web of Science ®Google Scholar
• Rai, E., S. Sharma, S. Kaul, et al. 2012. The interactive effect of SIRT1 promoter region polymorphism on type 2 diabetes susceptibility in the North Indian population. PLoS One 7: e48621
   PubMed Web of Science ®Google Scholar
• Naqvi, A., T. A. Hoffman, J. DeRicco, et al. 2010. A single-nucleotide variation in a p53-binding site affects nutrient-sensitive human SIRT1 expression. Hum. Mol. Genet. 19: 4123–4133
   PubMed Web of Science ®Google Scholar
• Watanabe, M., N. Yamamoto, H. Maruoka, et al. 2002. Independent involvement of CD8+ CD25+ cells and thyroid autoantibodies in disease severity of Hashimoto’s disease. Thyroid 12: 801–808
   PubMed Web of Science ®Google Scholar
• Jia, Y., P. Gao, H. Chen, et al. 2013. SIRT1 suppresses PMA and ionomycin-induced ICAM-1 expression in endothelial cells. Sci. China Life Sci. 56: 19–25
   PubMed Web of Science ®Google Scholar
• Wendling, D., W. Abbas, M. Godfrin-Valnet, et al. 2013. Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis. Clin. Epigenet. 5: 10
   PubMed Web of Science ®Google Scholar
• Libermann, T. A., and D. Baltimore. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 10: 2327–2334
   PubMed Web of Science ®Google Scholar
• Brasier, A. R. 2010. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 86: 211–218
   PubMed Web of Science ®Google Scholar
• Shakhov, A. N., M. A. Collart, P. Vassalli, et al. 1990. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 171: 35–47
   PubMed Web of Science ®Google Scholar
• Hirano, T., T. Taga, N. Nakano, et al. 1985. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc. Natl. Acad. Sci. USA 82: 5490–5494
   PubMed Web of Science ®Google Scholar
• Hirano, T., K. Yasukawa, H. Harada, et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73–76
   PubMed Web of Science ®Google Scholar
• Mitamura, K., H. Kang, Y. Tomita, et al. 1991. Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 85: 386–391
   PubMed Web of Science ®Google Scholar
• Rieckmann, P., J. M. Tuscano, and J. H. Kehrl. 1997. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods 11: 128–132
   PubMed Web of Science ®Google Scholar
• Rieckmann, P., F. D’Alessandro, and R. P. Nordan. 1991. IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. J. Immunol. 146: 3462–3468
   PubMed Web of Science ®Google Scholar